Financial Performance - Revenue for the six months ended September 30, 2025, was HKD 22,774,000, representing a 1.98% increase from HKD 22,334,000 in the same period of 2024[4] - The company reported a pre-tax profit of HKD 35,000 compared to a pre-tax loss of HKD 2,038,000 in the previous year, indicating a significant turnaround[4] - Basic earnings per share improved to HKD 0.01 from a loss of HKD 0.51 per share in the prior year[5] - Total comprehensive income for the period was HKD 36,000, compared to a loss of HKD 2,048,000 in the same period last year[4] - The pre-tax profit for the six months ended September 30, 2025, was HKD 11,238,000, a decrease of 7.8% from HKD 12,188,000 in 2024[21] - The group recorded a profit attributable to the owners of the company of HKD 35,000 for the six months ended September 30, 2025, compared to a loss of HKD 2.0 million for the same period in 2024[41] Assets and Liabilities - Non-current assets decreased to HKD 19,098,000 from HKD 20,298,000 as of March 31, 2025[6] - Current assets decreased to HKD 30,905,000 from HKD 37,145,000, primarily due to a reduction in cash and cash equivalents[6] - The company’s total liabilities decreased from HKD 43,313,000 to HKD 38,754,000, reflecting improved financial stability[6] - The group reported a net current liability of HKD 7,849,000 as of September 30, 2025, primarily due to contract liabilities amounting to HKD 20,897,000[13] - The group’s total equity as of September 30, 2025, was HKD 4.2 million, unchanged from March 31, 2025[53] - The group’s debt-to-asset ratio as of September 30, 2025, was 39.8%, slightly up from 39.7% on March 31, 2025[54] Cash Flow - Cash used in operating activities was HKD 1,372,000, a decline from cash generated of HKD 982,000 in the previous year[8] - The company incurred a net cash outflow of HKD 4,853,000 in the six months ended September 30, 2025, compared to an inflow of HKD 6,017,000 in the same period last year[8] - The group expects to generate sufficient cash flow in the next twelve months to meet its obligations, with available undrawn bank loan facilities of HKD 18,000,000[13] Revenue Breakdown - The revenue breakdown includes HKD 462,000 from medical consultation services, HKD 3,797,000 from prescription and dispensing services, and HKD 18,515,000 from treatment services[16] - The group's revenue for the six months ended September 30, 2025, increased by approximately HKD 0.4 million or 2.0% to HKD 22.8 million, compared to HKD 22.3 million for the same period in 2024[43] - The number of customers for treatment services increased, contributing to the revenue growth[43] Other Income and Expenses - Other income for the six months ended September 30, 2025, totaled HKD 797,000, compared to HKD 634,000 for the same period in 2024, reflecting an increase of 25.8%[20] - Employee costs decreased by approximately HKD 1.0 million or 7.8% to HKD 11.2 million for the six months ended September 30, 2025[46] - Depreciation of right-of-use assets decreased by approximately HKD 1.0 million or 26.9% to HKD 2.7 million for the six months ended September 30, 2025, due to reduced rental expenses[47] Share Capital and Dividends - The company has maintained its share capital at HKD 3,967,000 with reserves increasing to HKD 264,000 from HKD 228,000[6] - The total number of issued shares remained at 396,736,000 as of September 30, 2025, with a par value of HKD 0.01 per share[33] - The company did not declare an interim dividend for the six months ended September 30, 2025, consistent with 2024[25] Strategic Initiatives - The company’s management discussed the strategic positioning of its Medicskin and facematter brands, focusing on medical skin care and aesthetic treatments[38] - The group plans to enhance resilience and competitiveness by continuing operational optimization and improving marketing strategies[42] - The group aims to expand brand awareness and identify new business opportunities through strategic initiatives[42] Market Environment - The global business environment remains uncertain due to geopolitical tensions and high tariffs imposed by the U.S., impacting business confidence in Hong Kong[39] - The company’s management noted a shift in consumer behavior, with local residents increasingly opting for overseas travel and spending in the Greater Bay Area, affecting local market consumption[39] Share Option Scheme - The company has adopted a new share option scheme on September 27, 2024, allowing eligible employees to subscribe for shares[62] - The old share option scheme was terminated at the annual general meeting held on September 27, 2024[74] - The new share option plan has been approved by shareholders at the 2024 Annual General Meeting to attract and retain top talent, effective from September 27, 2024, for a duration of 10 years[75] - No share options were granted, exercised, vested, lapsed, or cancelled for the six months ending September 30, 2025[76] - The new share option plan allows for the grant of options involving 39,673,600 shares and 7,934,720 shares under specific limits for service providers[76] - The remaining term of the new share option plan is approximately 9 years[76] Governance and Compliance - The Audit Committee, consisting of three independent non-executive directors, has reviewed the unaudited interim financial statements for the six months ending September 30, 2025, ensuring compliance with applicable accounting standards and GEM listing rules[77]
密迪斯肌(08307) - 2026 - 中期财报